Healthcare technology company Zenosense (OTC: ZENO), a co-owner of the United Kingdom’s MIDS Medical Limited (“MML”) and its innovative handheld MIDS technology, is engaged in the ongoing development of its innovative MIDS Cardiac device. A recent article about the company reads: “MIDS Cardiac aims is to deliver true laboratory accuracy, performing high-sensitivity troponin tests in the emergency room or out in the field to better identify if a patient with chest pain or shortness of breath is experiencing a myocardial infarction. Troponin is a heart protein generally searched for by emergency room physicians as a quick indicator if damaged cardiac cells have entered the blood stream, and new age high-sensitivity troponin tests are delivering critical information to doctors more rapidly than before. … The majority of patients presenting themselves with chest pain or shortness of breath are ultimately found to not be experiencing acute heart attacks, but the critical concern associated with their symptoms can lead to unnecessary hospital admissions and tests that increase the medical expenses borne largely by patients and their insurance providers.”
To view the full article, visit http://nnw.fm/69ZLf
About Zenosense, Inc.
Zenosense Inc., through a joint-venture ownership in MIDS Medical Ltd., is primarily focused on the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac. MIDS Medical applies patent-protected magnetic nanoparticle detection technology and a development team with world-class technical expertise. The MIDS Cardiac device and test strip is being designed to support a variety of rapid high sensitivity cardiac biomarker tests, with a focus on troponin I and T, to identify or discount Acute Myocardial Infarction with accuracy equal or superior to high sensitivity assays performed on laboratory analyzers. For more information, visit the company’s website at www.Zenosense.com.
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com
New York, New York